



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BNC375

Cat. No.:	HY-128575
CAS No.:	1557240-80-8
Molecular Formula:	C ₁₉ H ₂₃ ClN ₂ O ₃ S
Molecular Weight:	394.92
Target:	nAChR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 83.33 mg/mL (211.00 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.5322 mL	12.6608 mL	25.3216 mL
		5 mM		0.5064 mL	2.5322 mL	5.0643 mL
		10 mM		0.2532 mL	1.2661 mL	2.5322 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.27 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.27 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.27 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC ₅₀ of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. ^[1]
In Vitro	BNC375 significantly potentiates the acetylcholine signal without changing the rapid receptor desensitization ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	BNC375 (0.003-10.0 mg/kg, administered orally) exhibits the MED of 0.03 mg/kg, and achieves full reversal of the

Scopolamine-induced impairment at 1.0 mg/kg in mouse T-maze model. BNC375 exhibits the plasma half-life ($t_{1/2}$) of 1.2 h^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Andrew J Harvey, et al. Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of $\alpha 7$ nAChRs. ACS Med Chem Lett. 2019 Mar 25;10(5):754-760.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA